Electronic Supplementary Information

Direct *N*-acylation of azoles via metal-free catalyzed oxidative crosscoupling strategy

Jingjing Zhao,^{ab} Pan Li,^a Chungu Xia^a and Fuwei Li*^a

[†] State Key Laboratory for Oxo Synthesis and Selective Oxidation, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou 730000, P. R. China

[‡]Graduate University of Chinese Academy of Sciences, Beijing 100049, P. R. China.

Email: fuweili@licp.cas.cn

Electronic Supplementary Information Contents:

General Information	ESI2
General Procedure for <i>N</i> -Acylation of Azoles	ESI2
General Procedure for Radical Trapping Experiments	ESI3
General Procedure for Control Experiments	ESI4-ESI6
Characterization of the Products	ESI8-ESI15
References and Notes	SESI16
Copies of ¹ H and ¹³ C NMR Spectra	ESI17-ESI44

General Information:

All reagents purchased from commercial sources were used as received. The silica gel for column chromatography was supplied as 300–400 meshes. The ¹H and ¹³C NMR spectra were recorded on a Bruker AVANCE III spectrometer and are referenced to the residual solvent signals (7.26 ppm for ¹H and 77.0 ppm for ¹³C in CDCl₃). The HRMS spectra were recorded on a Bruker micrOTOF Q II spectrometer.

General Procedure for N-Acylation of Azoles (3, 5):



To a 15 mL pressure tube with a stir bar was added 0.3 mmol of azole 1, 4, 0.45 mmol of aldehyde 2 or benzil (1.5 equiv), followed by 0.06 mmol of KI (0.2 equiv). Then 3 mL of DCE was added, followed by 0.9 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 100 °C for 12 h, cooled to room temperature, poured into brine and extracted with EtOAc. The combined extracts were dried over MgSO₄, filtered, and evaporated. The residue was purified by column chromatography (petroleum ether/EtOAc) to afford the desired product **3**, **5**.



To a 100 mL round-bottom flask with a stir bar was added 20 mmol of benzoimidazole, 30 mmol of benzaldehyde (1.5 equiv), followed by 4 mmol of KI (0.2 equiv). Then 25 mL of DCE was added, followed by 60 mmol of TBHP (70% aqueous). The flask with a condenser was open in air. The reaction mixture was stirred at 100 °C for 12 h, cooled to room temperature, poured into brine and extracted with EtOAc. The combined extracts were dried over MgSO₄, filtered, and evaporated. The residue was purified by column chromatography (petroleum ether/EtOAc) to afford the desired product **5a** (3.78 g, 85% yield).

General Procedure for Radical Trapping Experiments:



To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 5-phenyl-1*H*-pyrazole **1a**, 0.45 mmol of 3,4-dimethoxybenzaldehyde **2a** (1.5 equiv), followed by 0.06 mmol of KI (0.2 equiv). Then 3 mL of DCE was added, followed by 0.9 mmol of TBHP (70% aqueous) and 0.9 mmol of TEMPO (2,2,6,6-Tetramethylpiperidinooxy). The reaction mixture was stirred at 100 °C for 12 h, cooled to room temperature, poured into brine and extracted with EtOAc. The combined extracts were dried over MgSO₄, filtered, and evaporated. The residue was purified by column chromatography (petroleum ether/EtOAc) to afford **6** in 99% yield.



To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 5-phenyl-1*H*-pyrazole **1a**, 0.45 mmol of 3,4-dimethoxybenzaldehyde **2a** (1.5 equiv), followed by 0.06 mmol of KI (0.2 equiv). Then 3 mL of DCE was added, followed by 0.9 mmol of TBHP (70% aqueous) and 0.9 mmol of 1,1-Diphenylethylene. The reaction mixture was stirred at 100 °C for 12 h, cooled to room temperature. Only trace **3a** was detected by GC-MS.



To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 5-phenyl-1*H*-pyrazole **1a**, 0.45 mmol of benzil (1.5 equiv), followed by 0.06 mmol of KI (0.2 equiv). Then 3 mL of DCE was added, followed by 0.9 mmol of TBHP (70% aqueous) and 0.9 mmol of TEMPO. The reaction mixture was stirred at 100 °C for 12 h, cooled to room temperature. The desired product was not detected by GC-MS.

General Procedure for Control Experiments:



To a 15 mL pressure tube with a stir bar was added 0.3 mmol of pyrazole **1a**, 0.45 mmol of aliphatic aldehyde (1.5 equiv), followed by 0.06 mmol of KI (0.2 equiv). Then 3 mL of DCE was added, followed by 0.9 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 100 °C for 12 h, cooled to room temperature. The desired product was not detected by GC-MS. The pyrazole **1a** and corresponding aliphatic aldehyde were recovered, unusual product was not detected by GC-MS.



To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 3-phenylpropanal, 0.9 mmol of TEMPO, followed by 0.06 mmol of KI (0.2 equiv). Then 3 mL of DCE was added, followed by 0.9 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 100 °C for 12 h, cooled to room temperature. The corresponding aliphatic aldehyde was recovered, and the coupling product of 3-phenylpropanal and TEMPO was not detected by GC-MS.



To a 15 mL pressure tube with a stir bar was added 0.3 mmol of benzaldehyde, 0.36 mmol of butan-1-amine (1.2 equiv), followed by 0.015 mmol of KI (0.05 equiv). Then 3 mL of H_2O was added, followed by 0.66 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 80 °C for 15 h, cooled to room temperature. The amide was detected as the major product by GC-MS.



To a 15 mL pressure tube with a stir bar was added 0.3 mmol of benzaldehyde, 0.36 mmol of butan-1-amine (1.2 equiv), followed by 0.015 mmol of KI (0.05 equiv) and 0.66 mmol of TEMPO (2.2 equiv). Then 3 mL of H₂O was added, followed by 0.66 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 80 °C for 15 h, cooled to room temperature. The amide and the coupling product of acyl radical and TEMPO were not detected by GC-MS. Instead, the imine product was observed as the major product by GC-MS.

To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 4-chlorobenzaldehyde, 0.36 mmol of morpholine (1.2 equiv). Then 3 mL of CH₃CN was added, followed by 0.36 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 80 °C for 5 h, cooled to room temperature. The amide was detected as the major product by GC-MS.

To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 4-chlorobenzaldehyde, 0.36 mmol of morpholine (1.2 equiv), followed by 0.66 mmol of TEMPO (2.2 equiv). Then 3 mL of CH₃CN was added, followed by 0.36 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 80 °C for 5 h, cooled to room temperature. Only trace amide was detected by GC-MS. And the coupling product of acyl radical and TEMPO were not detected by GC-MS.



To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 3,4-dimethoxybenzaldehyde 2a, 0.36 mmol of 3-phenyl-1H-pyrazole 1a (1.2 equiv), followed by 0.015 mmol of KI (0.05 equiv). Then 3 mL of H₂O was added, followed by 0.66 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 80 °C for 15 h, cooled to room temperature. Only trace 3a was detected by GC-MS.



To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 3,4-dimethoxybenzaldehyde 2a, 0.36 mmol of 3-phenyl-1H-pyrazole 1a (1.2 equiv). Then 3 mL of CH₃CN was added, followed by 0.36 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 80 °C for 5 h, cooled to room temperature. Only trace 3a was detected by GC-MS.

$$\begin{array}{c} \begin{array}{c} \begin{array}{c} & \text{KI} (20 \text{ mmol}\%) \\ \hline \text{TBHP} (3 \text{ equiv}) \\ \hline \text{DCE}, 100 \ ^{\circ}\text{C} \end{array} \end{array} \begin{array}{c} \text{Ph} \\ \hline \text{N} & \text{N} \\ \hline \text{N} & \text{O} \\ \hline \text{N} & \text{O} \end{array} \end{array} \begin{array}{c} \begin{array}{c} \text{equation} \\ \text{equation} \\ \hline \text{N.D.} \end{array}$$

9

To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 5-phenyl-1*H*-pyrazole **1a**, 0.9 mmol of TEMPO, followed by 0.06 mmol of KI (0.2 equiv). Then 3 mL of DCE was added, followed by 0.9 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 100 °C for 12 h, cooled to room temperature. The coupling product of **1a** and TEMPO was not detected by GC-MS.

$$\begin{array}{c} \text{KI}(20\%)\\ \hline \\ \text{Ph} & \\ N' & \\ \hline \\ 0.3 \text{ mmol} \\ \end{array} \begin{array}{c} \text{KI}(20\%)\\ \hline \\ \text{TBHP}(3 \text{ equiv})\\ \hline \\ \text{DCE, 100 °C} \\ \hline \\ \text{N.D.} \\ \end{array} \begin{array}{c} \text{Ph} & \\ \hline \\ N & \\ N.D. \\ \end{array} \begin{array}{c} \text{equation 10}\\ \hline \\ \text{N.D.} \\ \end{array}$$

To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 5-phenyl-1*H*-pyrazole **1a**, followed by 0.06 mmol of KI (0.2 equiv). Then 3 mL of DCE was added, followed by 0.9 mmol of TBHP (70% aqueous). The reaction mixture was stirred at 100 °C for 12 h, cooled to room temperature. The 1-iodo-3-phenyl-1*H*-pyrazole was not detected by GC-MS.

$$\begin{array}{ccc} & & & \\ Ph & & \\ N' & NH & + & l_2 \text{ or NIS} & & \\ \hline & & DCE, rt & & Ph & & \\ \hline & & & N-N_1 & \\ 0.3 \text{ mmol} & 1 \text{ equiv} & & N.D. \end{array}$$

To a 15 mL pressure tube with a stir bar was added 0.3 mmol of 5-phenyl-1*H*-pyrazole **1a**, followed by 0.3 mmol of I_2 or NIS (1 equiv). Then 3 mL of DCE was added. The reaction mixture was stirred at room temperature for 12 h. The 1-iodo-3-phenyl-1*H*-pyrazole was not detected by GC-MS.

Characterization Data of Compounds 3a-3p:



(3,4-dimethoxyphenyl)(5-phenyl-1*H*-pyrazol-1-yl)methanone(3a) [Newcompound]. 1 H NMR (400 MHz, CDCl₃) δ 8.48 (d, J = 2.9 Hz, 1 H), 8.14 (dd, J = 8.5, 2.1 Hz, 1 H),7.96 (d, J = 2.0 Hz, 1 H), 7.93–7.87 (m, 2 H), 7.50-7.36 (m, 3 H), 6.99 (t, J = 8.2 Hz, 1 H), 6.85 (d, J = 2.9 Hz, 1 H), 4.00 (s, 3 H), 3.98 (s, 3 H); 13 C NMR (100 MHz, CDCl₃) δ 164.9, 155.6, 153.4, 148.3,132.0, 132.0, 129.1, 128.8, 127.2, 126.3, 123.5, 114.7, 110.1, 106.7, 56.1, 56.0; HRMS (ESI) Calcd for $C_{18}H_{16}N_2NaO_3$ [M+Na] 331.1066, Found 331.1053.



phenyl(5-phenyl-1*H***-pyrazol-1-yl)methanone (3b)** [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, *J* = 2.9 Hz, 1 H), 8.31–8.25 (m, 2 H), 7.93–7.87 (m, 2 H), 7.68–7.62 (m, 1 H), 7.58–7.51 (m, 2 H), 7.47–7.37 (m, 3 H), 6.87 (d, *J* = 2.9 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.1, 155.9, 133.0, 131.9, 131.8, 131.7, 131.5, 129.2, 128.7, 128.0, 126.4, 107.2; HRMS (ESI) Calcd for C₁₆H₁₂N₂NaO [M+Na] 271.0844, Found 271.0842.



(4-methoxyphenyl)(5-phenyl-1*H***-pyrazol-1-yl)methanone (3c) [New compound].** ¹H NMR (400 MHz, CDCl₃) δ 8.47 (t, *J* = 3.6 Hz, 1 H), 8.42–8.35 (m, 2 H), 7.92–7.89 (m, 2 H), 7.50– 7.37 (m, 3 H), 7.05–6.99 (m, 2 H), 6.84 (d, *J* = 2.9 Hz, 1 H), 3.91 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 165.1, 163.6, 155.5, 134.5, 132.0, 131.8, 129.0, 128.7, 126.3, 123.5, 113.4, 106.7, 55.5; HRMS (ESI) Calcd for C₁₇H₁₄N₂NaO₂ [M+Na] 301.0962, Found 301.0947.



(4-(*tert*-butyl)phenyl)(5-phenyl-1*H*-pyrazol-1-yl)methanone(3d)[Newcompound]. ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, J = 2.9 Hz, 1 H), 8.31 – 8.22 (m, 2 H), 7.96 –7.88 (m, 2 H), 7.61 – 7.54 (m, 2 H), 7.50 – 7.37 (m, 3 H), 6.86 (d, J = 2.9 Hz, 1 H), 1.40 (s, 9 H); ¹³CNMR (100 MHz, CDCl₃) δ 165.8, 156.8, 155.7, 132.0, 131.9, 131.7, 129.1, 128.7, 128.5, 126.4, 125.1,106.9, 35.1, 31.1; HRMS (ESI) Calcd for C₂₀H₂₀N₂NaO [M+Na] 327.1460, Found 327.1468.



(4-bromophenyl)(5-phenyl-1*H*-pyrazol-1-yl)methanone (3e) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.18 (s, 1 H), 8.18–8.13 (m, 1 H), 7.85–7.83 (m, 1 H), 7.78–7.72 (m, 2 H), 7.68 (dd, *J* = 8.6, 1.9 Hz, 2 H), 7.51–7.39 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.1, 144.1, 142.6, 132.4, 132.0, 131.6, 131.0, 128.4, 125.9, 125.4, 120.7, 115.4; HRMS (ESI) Calcd for C₁₄H₉BrN₂NaO [M+Na] 322.9782, Found 322.9790.



(4-chlorophenyl)(5-phenyl-1*H*-pyrazol-1-yl)methanone (3f) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, J = 2.9 Hz, 1 H), 8.31–8.23 (m, 2 H), 7.93–7.84 (m, 2 H), 7.54– 7.50 (m, 2 H), 7.48–7.38 (m, 3 H), 6.88 (d, J = 2.9 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 165.0, 156.1, 139.6, 133.4, 131.7, 131.6, 129.8, 129.3, 128.8, 128.4, 126.4, 107.4; HRMS (ESI) Calcd for C₁₆H₁₁ClN₂NaO [M+Na] 305.0448, Found 305.0452.



4-(5-phenyl-1*H***-pyrazole-1-carbonyl)benzonitrile (3g) [New compound].** ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, J = 2.9 Hz, 1 H), 8.34 (d, J = 8.2 Hz, 2 H), 7.90–7.79 (m, 4 H), 7.48–7.40 (m, 3 H), 6.91 (d, J = 2.9 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 164.5, 156.6, 135.4, 132.1, 131.7, 131.6, 131.2, 129.5, 128.8, 126.4, 117.9, 116.1, 108.0; HRMS (ESI) Calcd for C₁₇H₁₁N₃NaO [M+Na] 296.0794, Found 296.0794.



(2-methoxyphenyl)(5-phenyl-1*H*-pyrazol-1-yl)methanone (3h) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.29 (d, *J* = 2.9 Hz, 1 H), 7.86–7.78 (m, 2 H), 7.59–7.50 (m, 2 H), 7.42– 7.35 (m, 3 H), 7.09–7.03 (m, 2 H), 6.81 (d, *J* = 2.9 Hz, 1 H), 3.82 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 196.5, 157.9, 155.7, 132.7, 131.9, 131.1, 130.5, 129.1, 128.6, 126.4, 122.7, 120.2, 111.6, 107.3, 55.9; HRMS (ESI) Calcd for C₁₇H₁₄N₂NaO₂ [M+Na] 301.0954, Found 301.0947.



(3-fluorophenyl)(5-phenyl-1*H*-pyrazol-1-yl)methanone (3i) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, J = 2.9 Hz, 1 H), 8.11–8.07 (m, 1 H), 8.07–8.02 (m, 1 H), 7.92–7.86 (m, 2 H), 7.51 (td, J = 8.0, 5.6 Hz, 1 H), 7.48–7.38 (m, 3 H), 7.35 (tdd, J = 8.3, 2.6, 0.9 Hz, 1 H), 6.89 (d, J = 2.9 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 164.7, 162.1 (¹J_{CF} = 246.8 Hz), 156.3, 133.4 (³J_{CF} = 7.8 Hz), 131.8, 131.6, 129.7 (³J_{CF} = 7.8 Hz), 129.4, 128.8, 127.7 (⁴J_{CF} = 3.2 Hz), 126.4, 120.1

 $({}^{2}J_{CF} = 21.3 \text{ Hz})$, 119.0 (${}^{1}J_{CF} = 24.1 \text{ Hz}$), 107.6; HRMS (ESI) Calcd for C₁₆H₁₁FN₂NaO [M+Na] 289.0740, Found 289.0748.



(3,5-dimethoxyphenyl)(5-phenyl-1*H*-pyrazol-1-yl)methanone(3j)[Newcompound].¹H NMR (400 MHz, CDCl₃) δ 8.46 (d, J = 2.9 Hz, 1 H), 7.93–7.85 (m, 2 H),7.46–7.39 (m, 5 H), 6.87 (d, J = 2.9 Hz, 1 H), 6.73 (t, J = 2.3 Hz, 1 H), 3.87 (s, 6 H); ¹³C NMR (100MHz, CDCl₃) δ 165.7, 160.2, 155.9, 133.0, 132.0, 131.8, 129.2, 128.8, 126.3, 109.6, 107.2, 105.9, 55.6;HRMS (ESI) Calcd for C₁₈H₁₆N₂NaO₃ [M+Na] 331.1054, Found 331.1053.



naphthalen-2-yl(5-phenyl-1*H*-pyrazol-1-yl)methanone (3k) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.93 (s, 1 H), 8.54 (d, J = 2.9 Hz, 1 H), 8.31–8.24 (m, 1 H), 8.03 (d, J = 8.1 Hz, 1 H), 7.97 (d, J = 8.7 Hz, 1 H), 7.94–7.91 (m, 3 H), 7.67–7.63 (m, 1 H), 7.61–7.57 (m, 1 H), 7.50–7.37 (m, 3 H), 6.90 (d, J = 2.9 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.1, 155.9, 135.4, 134.1, 132.2, 131.8, 129.7, 129.2, 128.8, 128.6, 127.7, 127.6, 127.1, 126.7, 126.4, 107.1; HRMS (ESI) Calcd for C₂₀H₁₄N₂NaO [M+Na] 321.1000, Found 321.0998.



(5-phenyl-1*H*-pyrazol-1-yl)(thiophen-2-yl)methanone (3l) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.48 (dd, J = 3.9, 1.3 Hz, 1 H), 8.46 (d, J = 2.9 Hz, 1 H), 7.98 (dd, J = 5.3,

3.3 Hz, 2 H), 7.84 (dd, J = 5.0, 1.3 Hz, 1 H), 7.53–7.46 (m, 2 H), 7.43 (ddd, J = 7.4, 3.7, 1.3 Hz, 1 H), 7.22 (dd, J = 4.9, 4.0 Hz, 1 H), 6.86 (d, J = 2.9 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 158.6, 155.5, 138.5, 137.7, 132.2, 131.7, 130.8, 129.2, 128.8, 127.2, 126.4, 107.3; HRMS (ESI) Calcd for C₁₄H₁₀N₂NaOS [M+Na] 277.0398, Found 277.0406.



(4-bromophenyl)(3-methyl-1*H*-pyrazol-1-yl)methanone (3m) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.31 (d, J = 2.7 Hz, 1 H), 8.08–7.99 (m, 2 H), 7.67–7.61 (m, 2 H), 6.34 (d, J = 2.8 Hz, 1 H), 2.35 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 165.1, 154.7, 133.1, 131.4, 131.1, 130.5, 128.1, 110.5, 14.0; HRMS (ESI) Calcd for C₁₁H₉BrN₂NaO [M+Na] 286.9786, Found 286.9790.



(4-bromophenyl)(1*H*-pyrazol-1-yl)methanone (3n) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.43 (dd, J = 2.9, 0.5 Hz, 1 H), 8.08–7.99 (m, 2 H), 7.80 (d, J = 0.7 Hz, 1 H), 7.71–7.62 (m, 2 H), 6.53 (dd, J = 2.8, 1.5 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 165.4, 144.7, 133.1, 131.4, 130.4, 130.2, 128.3, 109.7; HRMS (ESI) Calcd for C₁₀H₇BrN₂NaO [M+Na] 272.9639, Found 272.9634.



(1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (5a)¹. ¹H NMR (400 MHz, CDCl₃) δ 8.22 (s, 1 H), 8.22–8.19 (m, 1 H), 7.87–7.83 (m, 1 H), 7.81 (dd, *J* = 5.2, 3.3 Hz, 2 H), 7.74–7.67 (m, 1 H), 7.62–7.58 (m, 2 H), 7.49–7.41 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 167.1, 144.1, 143.1, 133.2, 132.9, 132.1, 129.5, 129.1, 125.8, 125.3, 120.6, 115.5; HRMS (ESI) Calcd for C₁₄H₁₁N₂O [M+H] 223.0866, Found 223.0866.



(1*H*-benzo[*d*]imidazol-1-yl)(4-bromophenyl)methanone (5b) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.18 (s, 1 H), 8.18–8.13 (m, 1 H), 7.85–7.83 (m, 1 H), 7.78–7.72 (m, 2 H), 7.68 (dd, *J* = 8.6, 1.9 Hz, 2 H), 7.51–7.39 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.1, 144.1, 142.6, 132.4, 132.0, 131.6, 131.0, 128.4, 125.9, 125.4, 120.7, 115.4; HRMS (ESI) Calcd for C₁₄H₉BrN₂NaO [M+Na] 322.9782, Found 322.9790.



4-(1*H***-benzo[***d***]imidazole-1-carbonyl)benzonitrile (5c) [New compound].** ¹H NMR (400 MHz, CDCl₃) δ 8.21–8.14 (m, 1 H), 8.12 (s, 1 H), 7.97–7.88 (m, 4 H), 7.87–7.82 (m, 1 H), 7.51–7.43 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 165.3, 144.1, 142.3, 136.7, 132.9, 131.8, 129.9, 126.3, 125.9, 120.9, 117.4, 116.8, 115.5; HRMS (ESI) Calcd for C₁₅H₉N₃NaO [M+Na] 270.0630, Found 270.0638.



(1*H*-benzo[*d*]imidazol-1-yl)(2-methoxyphenyl)methanone (5d) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.30–8.21 (m, 1 H), 7.97 (s, 1 H), 7.86–7.73 (m, 1 H), 7.59 (m, 1 H), 7.54 (dd, *J* = 7.6, 1.6 Hz, 1 H), 7.48–7.37 (m, 2 H), 7.14 (td, *J* = 7.5, 0.8 Hz, 1 H), 7.06 (d, *J* = 8.4 Hz, 1 H), 3.78 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 165.8, 156.5, 144.1, 143.6, 133.5, 131.6, 129.9, 125.7, 125.1, 122.9, 121.2, 120.3, 115.5, 111.6, 55.7; HRMS (ESI) Calcd for C₁₅H₁₂N₂NaO₂ [M+Na] 275.0794, Found 275.0791.



(1*H*-benzo[*d*]imidazol-1-yl)(2-bromophenyl)methanone (5e) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J* = 5.4 Hz, 1 H), 7.90 (s, 1 H), 7.87–7.81 (m, 1 H), 7.76–7.74 (m, 1 H), 7.60–7.39 (m, 5 H); ¹³C NMR (100 MHz, CDCl₃) δ 165.2, 144.2, 142.7, 135.3, 133.5, 132.6, 131.3, 129.2, 127.9, 126.029, 125.5, 120.6, 119.7, 115.4; HRMS (ESI) Calcd for C₁₄H₉BrN₂NaO [M+Na] 322.9793, Found 322.9790.



(1*H*-benzo[*d*]imidazol-1-yl)(3,4-dimethoxyphenyl)methanone (5f) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.31 (s, 1 H), 8.17–8.09 (m, 1 H), 7.89–7.80 (m, 1 H), 7.48–7.38 (m, 4 H), 7.06–6.95 (m, 1 H), 4.00 (s, 3 H), 3.96 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.4, 153.5, 149.4, 144.0, 143.1, 132.3, 125.5, 125.0, 124.8, 124.1, 120.4, 115.2, 112.3, 110.4, 56.2, 56.1; HRMS (ESI) Calcd for C₁₆H₁₄N₂NaO₃ [M+Na] 305.0902, Found 305.0897.



(1*H*-benzo[*d*]imidazol-1-yl)(3-nitrophenyl)methanone (5g) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.69 (t, *J* = 1.9 Hz, 1 H), 8.56 (ddd, *J* = 8.3, 2.2, 1.0 Hz, 1 H), 8.23–8.17 (m, 1 H), 8.16 (s, 1 H), 8.16–8.12 (m, 1 H), 7.91–7.81 (m, 2 H), 7.54–7.44 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 164.6, 148.4, 144.1, 142.1, 134.8, 134.5, 131.8, 130.5, 127.6, 126.3, 125.9, 124.5, 120.9, 115.5; HRMS (ESI) Calcd for C₁₄H₁₀N₃O₃ [M+H] 268.0712, Found 268.0717.



(1*H*-benzo[*d*]imidazol-1-yl)(naphthalen-2-yl)methanone (5h) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.31 (s, 2 H), 8.26–8.19 (m, 1 H), 8.04 (d, *J* = 8.5 Hz, 1 H), 7.96 (d, *J* = 8.7 Hz, 2 H), 7.90–7.83 (m, 2 H), 7.72–7.66 (m, 1 H), 7.65–7.60 (m, 1 H), 7.50–7.42 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 167.1, 144.1, 143.2, 135.3, 132.2, 131.1, 129.9, 129.2, 129.0, 128.0, 127.5, 125.7, 125.2, 125.0, 120.6, 115.4; HRMS (ESI) Calcd for C₁₈H₁₂N₂NaO [M+Na] 295.0849, Found 295.0842.



(1*H*-benzo[*d*]imidazol-1-yl)(thiophen-2-yl)methanone (5i) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.54 (s, 1 H), 8.23–8.14 (m, 1 H), 7.88–7.80 (m, 2 H), 7.81–7.76 (m, 1 H), 7.50–7.39 (m, 2 H), 7.28–7.26 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 159.9, 143.9, 142.2, 135.7, 134.5, 134.3, 132.2, 128.2, 125.7, 125.2, 120.5, 115.3; HRMS (ESI) Calcd for C₁₂H₉N₂OS [M+H] 229.0431, Found 229.0430.



(1*H*-benzo[*d*][1,2,3]triazol-1-yl)(phenyl)methanone (5j)². ¹H NMR (400 MHz, CDCl₃) δ 8.40 (d, *J* = 8.3 Hz, 1 H), 8.25–8.19 (m, 2 H), 8.17 (d, *J* = 8.3 Hz, 1 H), 7.74–7.67 (m, 2 H), 7.62–7.52 (m, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.7, 145.7, 133.7, 132.3, 131.7, 131.5, 130.4, 128.4, 126.3, 120.2, 114.8; HRMS (ESI) Calcd for C₁₃H₉N₃NaO [M+Na] 246.0630, Found 246.0638.



 1*H*-benzo[*d*][1,2,3]triazol-1-yl)(2-bromophenyl)methanone
 (5m)
 [New

 compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.41 (dd, *J* = 8.3, 0.7 Hz, 1 H), 8.16 (dd, *J* = 8.3, 0.7 Hz,

 1 H), 7.77–7.70 (m, 2 H), 7.64–7.60 (m, 1 H), 7.60–7.54 (m, 1 H), 7.53–7.44 (m, 2 H); ¹³C NMR (100

MHz, CDCl₃) δ 166.4, 146.2, 135.0, 133.2, 132.5, 131.3, 130.7, 130.1, 127.2, 126.7, 120.6, 120.4, 114.4; HRMS (ESI) Calcd for C₁₃H₈BrN₃NaO [M+Na] 323.9736, Found 323.9743.



(1*H*-benzo[*d*][1,2,3]triazol-1-yl)(2-methoxyphenyl)methanone (5n) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.39 (d, *J* = 8.3 Hz, 1 H), 8.13 (d, *J* = 8.3 Hz, 1 H), 7.69 (ddd, *J* = 8.2, 7.2, 1.0 Hz, 1 H), 7.63–7.50 (m, 3 H), 7.12 (td, *J* = 7.5, 0.8 Hz, 1 H), 7.06 (d, *J* = 8.4 Hz, 1 H), 3.77 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.9, 157.8, 146.0, 133.5, 131.4, 130.3, 130.2, 126.1, 122.7, 120.5, 120.1, 114.4, 111.7, 55.8; HRMS (ESI) Calcd for C₁₄H₁₁N₃NaO₂ [M+Na] 276.0738, Found 276.0743.



(4-bromophenyl)(1*H*-indazol-1-yl)methanone (50) [New compound]. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (dd, *J* = 8.4, 0.7 Hz, 1 H), 8.21 (d, *J* = 0.6 Hz, 1 H), 8.01-7.93 (m, 2 H), 7.83-7.76 (m, 1 H), 7.68-7.65 (m, 2 H), 7.64-7.61 (m, 1 H), 7.48-7.39 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 167.3, 140.6, 140.1, 132.6, 132.1, 131.3, 129.7, 127.3, 126.1, 125.0, 121.0, 115.9; HRMS (ESI) Calcd for C₁₄H₉BrN₂NaO [M+Na] 322.9789, Found 322.9790.



2,2,6,6-tetramethylpiperidin-1-yl 3,4-dimethoxybenzoate (6). ¹H NMR (400 MHz, CDCl₃) δ 7.67 (dd, J = 8.4, 1.5 Hz, 1 H), 7.54 (d, J = 1.5 Hz, 1 H), 6.86 (d, J = 8.4 Hz, 1 H), 3.89 (s, 6 H), 1.76-1.39 (m, 6 H), 1.22 (s, 6 H), 1.07 (s, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.0, 152.7, 148.6, 123.0, 121.9, 112.1, 110.1, 60.1, 55.8, 55.77, 38.8, 31.8, 20.6, 16.8; HRMS (ESI) Calcd for C₁₈H₂₇NNaO₄ [M+Na] 344.1825, Found 344.1832.

References:

- (1) H. R. J. Yajnanarayana and W. G. Harry, J. Org. Chem. 1991, 56, 865.
- (2) (a) R. K. Alam and P. Alfredo, J. Org. Chem. 1990, 65, 3679; (b) N. G. Gaylord and J. M. Naughton, J. Org. Chem. 1957, 22, 1022.

Copies of ¹H and ¹³C NMR Spectra



¹³C NMR of product **3a**



¹³C NMR of product **3b**



¹³C NMR of product **3**c



¹³C NMR of product **3d**



¹³C NMR of product **3e**



¹³C NMR of product **3f**



¹³C NMR of product **3**g



¹³C NMR of product **3h**



¹³C NMR of product **3i**



¹³C NMR of product **3**j



¹H NMR of product **3**k



¹³C NMR of product **3**k



¹³C NMR of product **3**I



¹³C NMR of product **3m**



¹³C NMR of product **3n**



¹³C NMR of product **5a**



¹³C NMR of product **5b**



¹³C NMR of product **5**c



¹³C NMR of product **5d**



¹³C NMR of product **5**e



¹³C NMR of product **5**f



¹³C NMR of product **5g**



¹H NMR of product **5h**





¹³C NMR of product **5h**



¹³C NMR of product **5**i



¹³C NMR of product **5**j



¹³C NMR of product **5m**







¹³C NMR of product **50**



¹³C NMR of product **6**